UBC Executive and Leadership Team

Bekki Brown, the President & Chief Executive Officer at UBC, directs the overarching strategy and operational execution for the global biopharmaceutical services organization. Overseeing all facets of the company, Brown ensures the integration of scientific expertise with advanced data analytics and technology-driven platforms to address complex challenges in drug development and commercialization. This leadership role involves guiding the company's mission to generate meaningful clinical and real-world evidence that informs regulatory, payer, and healthcare decision-making. By focusing on real-world conditions, Bekki Brown drives the development of solutions that support the safety, efficacy, and value assessment of medical products, solidifying UBC's position as a key partner for pharmaceutical and life sciences organizations worldwide. The strategic direction set by Brown directly impacts the company's ability to deliver critical insights and enhance patient outcomes through robust evidence generation.

Steve Bell, the Chief Financial Officer & Acco Principal at UBC, manages the company's financial operations and fiscal strategy. Bell oversees all aspects of financial planning, accounting, and reporting, ensuring robust fiscal health and compliance across the organization. This critical role involves managing financial resources to support UBC's global biopharmaceutical services, particularly its evidence development solutions. By providing strategic financial guidance, Steve Bell enables the company to invest in advanced data analytics and technology-driven platforms essential for generating real-world evidence. Bell's oversight ensures that financial decisions align with the company's mission to support the safety, efficacy, and value assessment of medical products. The financial integrity maintained by Bell is fundamental to informing regulatory, payer, and healthcare decision-making, underpinning the trust pharmaceutical and life sciences organizations place in UBC's services.

Dean Reiman, the President at UBC, drives operational excellence and strategic growth initiatives across the biopharmaceutical services organization. Reiman focuses on enhancing the delivery of evidence development solutions designed to support the safety, efficacy, and value assessment of medical products under real-world conditions. This leadership position involves close collaboration with pharmaceutical and life sciences organizations to ensure the generation of meaningful clinical and real-world evidence. By optimizing operational workflows, Dean Reiman facilitates the integration of scientific expertise with advanced data analytics and technology-driven platforms. Reiman's efforts are crucial for addressing complex challenges in drug development and commercialization, directly impacting the quality and timeliness of insights provided to regulatory, payer, and healthcare decision-makers. The operational leadership provided by Reiman ensures UBC consistently meets the evolving needs of its clients.

Michael Haratz, the Senior Vice President, Chief Legal Officer at UBC, provides comprehensive legal counsel and oversees all legal affairs for the global biopharmaceutical services organization. Haratz ensures that UBC's operations and evidence development solutions adhere to all relevant legal and regulatory frameworks, safeguarding the company's interests and compliance. This vital role involves managing corporate governance, intellectual property, and contractual agreements, supporting the company's mission to generate reliable real-world evidence. By guiding the legal aspects of drug development and commercialization, Michael Haratz enables UBC to effectively support the safety, efficacy, and value assessment of medical products. Haratz's expertise is critical in navigating the complex legal landscape that informs regulatory, payer, and healthcare decision-making, ensuring that all evidence generated meets the highest standards of integrity and legality.